MYC and breast cancer: The expression of amplified MYC proto-oncogene (MYC), cyclin D1 (CCND1), and Erb-B2 receptor tyrosine kinase 2 (ERBB2) in metastatic breast cancer compared to conditions without amplification indicated no significant correlation with UBE2C expression (Table 1 and Figure S2 panel 2E).